Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment

Progress in Retinal and Eye Research

Volumn 19, Issue 4, 2000, Pages 459-496

  Stjernschantz, Johan ^a   Selén, Göran ^b   Astin, Maria ^b   Resul, Bahram ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Pharmacia & Upjohn AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

15 KETO 17 PHENYL 18,19,20 TRINOR PROSTAGLANDIN F2 ALPHA ISOPROPYL ESTER; 17 PHENYL 18,19,20 TRINOR PROSTAGLANDIN E2 ISOPROPYL ESTER; 17 PHENYL 18,19,20 TRINOR PROSTAGLANDIN F2 ALPHA ISOPROPYL ESTER; 19 HYDROXYPROSTAGLANDIN E2; ALBUMIN I 125; ALBUMIN I 131; ERYTHROCYTE CR 51; EVANS BLUE; LATANOPROST; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN F2 ALPHA ISOPROPYL ESTER; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTANOID RECEPTOR; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

BLOOD EYE BARRIER; BLOOD VOLUME; CAPILLARY PERMEABILITY; CAT; EYE BLOOD FLOW; GLAUCOMA; HEART OUTPUT; MICROVASCULATURE; MONKEY; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; RABBIT; REVIEW; VASCULAR RESISTANCE; VASODILATATION;

ANIMALS; ANTERIOR EYE SEGMENT; ANTIHYPERTENSIVE AGENTS; BLOOD-AQUEOUS BARRIER; CAPILLARY PERMEABILITY; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; REGIONAL BLOOD FLOW; VASODILATION;

EID: 0034002299     PISSN: 13509462     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1350-9462(00)00003-3     Document Type: Review

References (131)

1. 2 receptor and receptor coupled functions in the choroidal vasculature of the pig during development. Circulation Res. 80:1997;463-472.
2. Alm A., Bill A. The oxygen supply to the retina. II. Effects of high intraocular pressure and of increased arterial carbon dioxide tension on uveal and retinal blood flow in cats. Acta Physiol. Scand. 84:1972;306-309.
3. Alm A., Bill A. Ocular and optic nerve blood flow at normal and increased intraocular pressure in monkeys (Macaca irus): A study with radioactively labeled microsperes including flow determination in brain and some other tissues. Exp. Eye Res. 15:1973;15-29.
4. Alm A., Törnquist P., Stjernschantz J. Radioactively labeled microspheres in regional ocular blood flow determinations. 9th European Conference on Microcirculation, Antwerp 1976. Bibliotheca Anatomica. 16:1977;24-29.
5. Alm A., Bill A. Ocular circulation. Moses R.A., Hart W.M. Jr. Adler's Physiology of the Eye. 1987;182-203 The C.V. Mosby Company, St. Louis/Washington/Toronto.
6. 2α and its isopropylester on normal and glaucomatous human eyes. Bito L.Z., Stjernschantz J. The Ocular Effects of Prostaglandins and Other Eicosanoids. 1989;447-458 Alan R. Liss Inc, New York.
7. Alm A., Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: A comparison with timolol. Ophthalmology. 102:1995;1743-1752.
8. Alm A., Camras C.B., Watson P.G. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv. Ophthalmol. 41:(Suppl. 2):1997;S105-S110.
9. Alm A. Prostaglandin derivates as ocular hypotensive agents. Prog. Retinal Eye Res. 17:1998;291-312.
10. 1. Europ. J. Pharmacol. 14:1971;66-70.
11. Änggård E., Larsson C., Samuelsson B. The distribution of 15-hydroxy prostaglandin dehydrogenase and prostaglandin-13-reductase in tissues of the swine. Acta. Physiol. Scand. 81:1971;396-404.
12. Änggård E., Flower R. Essential fatty acids and prostaglandins - an introductory overview. Vane J., O'Grady J. Therapeutic Applications of Prostaglandins. 1993;1-14 Edward Arnold, London.
13. 2α-induced ocular hyperemia. Exp. Eye Res. 59:1994;401-408.
14. 2α- and latanoprost acid-induced relaxation of submental veins. Europ. J. Pharmacol. 340:1997;195-201.
15. 2α, and latanoprost acid on isolated ocular blood vessels in vitro. J. Ocular Pharmacol. Therapeutics. 14:1998;119-128.
16. 2α and latanoprost in the eye - With special reference to the surface hyperaemia after topical administration. Compr. Summ. Uppsala Dissertations Faculty of Medicine. 179:1998.
17. Basu S., Sjöquist B., Stjernchantz J., Resul B. Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukot. Essent. Fatty Acids. 50:1994;161-168.
18. 13-reductase dependent metabolism of prostaglandins in the mammalian brain and eye. Prostaglandins Leukot. Essent. Fatty Acids. 57:1997;305-310.
19. Benezra D. Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemo-attractants. Am. J. Ophthalmol. 86:1978;455-461.
20. Bill A. The albumin exchange in the rabbit eye. Acta Physiol. Scand. 60:1964;18-29.
21. Bill A. Capillary permeability to and extravascular dynamics of myoglobin, albumin and gammaglobulin in the uvea. Acta Physiol. Scand. 73:1968;204-219.
22. Bill A. Effects of indomethacin on regional blood flow in conscious rabbits - A microsphere study. Acta Physiol. Scand. 105:1979;437-442.
23. Bill A., Stjernschantz J. Cholinergic vasoconstrictor effects in the rabbit eye: Vasomotor effects of pentobarbital anaesthesia. Acta Physiol. Scand. 108:1980;419-424.
24. Bito L.Z. Accumulation and apparent active transport of prostaglandins by some rabbit tissues in vitro. J. Physiol. (Lond). 221:1972;371-387.
25. Bito L.Z. Comparative study of concentrative prostaglandin accumulation by various tissues of mammals and marine vertebrates and invertebrates. Comp. Biochem. Physiol. 42A:1972;65-82.
26. Bito L.Z. Absorptive transport of prostaglandins from intraocular fluids to blood: A review of recent findings. Exp. Eye Res. 16:1973;299-306.
27. 2α-1-isopropyl ester. Exp. Eye Res. 44:1987;217-226.
28. Bito L.Z. Prostaglandins: A new approach to glaucoma management with a new, intriguing side effect. Surv. Ophthalmol. 41:(Suppl. 2):1997;S1-S14.
29. 4 have distinct microcirculatory actions in vivo. Adv. Tromboxane Leukotriene Res. 12:1983;1-6.
30. 2α esters across cornea in vitro. Int. J. Pharmaceutics. 29:1986;259-266.
31. 2α and its isopropyl ester in vitro. Int. J. Pharmaceutics. 37:1987;27-32.
32. Camras C.B., Bito L.Z., Eakins K.E. Reduction of intraocular pressure by prostaglandins applied topically to the rabbit eye. Invest. Ophthalmol. Vis. Sci. 16:(Suppl.):1977;57.
33. 2α. Curr. Eye Res. 1:1981;205-209.
34. 2α or epinephrine on cynomolgus monkey eyes. 1. Aqueous humor dynamics. Invest. Ophthalmol. Vis. Sci. 28:1987;463-469.
35. Camras C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month, masked multicenter trial in the United States. Ophthalmology. 103:1996;138-147.
36. Chemtob S., Beharry K., Rex J., Chatterjee T., Varma D.R., Aranda J.V. Ibuprofen enhances retinal and choroidal blood flow autoregulation in newborn piglets. Invest. Ophthalmol. Vis. Sci. 32:1991;1799-1807.
37. 2α metabolism by human ocular tissues. Invest. Ophthalmol. Vis. Sci. 21:1990;1389-1393.
38. Coleman R.A., Kennedy I., Humphrey P.P.A., Bunce K., Lumley P. Prostanoids and their receptors. Hansch C., Sammes P.G., Taylor J.B. Comprehensive Medicinal Chemistry. Vol. 3:1989;634-714 Pergamon Press, Oxford/New York.
39. Coleman R.A., Smith W.L., Narumiya S. VIII. International Union of Pharmacology. Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46:1994;205-229.
40. Cooper C.A., Bergamini M.V.W., Leopold I.H. Use of Flurbiprofen to inhibit corneal neovascularization. Arch. Ophthalmol. 98:1980;1102-1105.
41. 2α on aqueous humor dynamics in cynomolgus monkeys. Curr. Eye Res. 6:1987;1035-1044.
42. 2α on the cerebral circulation of dogs and monkeys. J. Neurosur. 36:1972;34-42.
43. Deutsch T.A., Hughes W.F. Suppressive effects of indomethacin on thermally induced neovascularization of rabbit corneas. Am. J. Ophthalmol. 87:1979;537-540.
44. Eakins K.E., Whitelock R.A.F., Bennett A., Martenet A.C. Prostaglandin-like activity in ocular inflammation. Br. J. Med. 19:1972;452-453.
45. 1 by ocular tissues in vitro. Exp. Eye Res. 19:1974;141-146.
46. Eakins K.E. Prostaglandin and non-prostaglandin mediated breakdown of the blood-aqueous barrier. Exp. Eye Res. 25:(Suppl.):1977;483-498.
47. 2 levels. Br. J. Ophthalmol. 68:1984;656-659.
48. Goh Y., Urade Y., Fujimoto N., Hayashi O. Content and formation of prostaglandins and distribution of prostaglandin-related enzyme activities in the rat ocular system. Biochim. Biophys. Acta. 921:1987;302-311.
49. Green K., Paterson C.A., Siddiqui A. Ocular blood flow after experimental alkali burns and prostaglandin administration. Arch. Ophthalmol. 103:1985;569-571.
50. Habib A., Vezza R., Creminon C., Maclouf J., FitzGerald G.A. Rapid, agonist-dependent phosphorylation in vivo of human thromboxane receptor isoforms. Minimal involvement of protein kinase C. J. Biol. Chem. 272:1997;7191-7200.
51. Hanss J.G., Taylor G.H. Metabolism and toxicology of the prostaglandins. Vane J., O'Grady J. Therapeutic Applications of Prostaglandins. 1993;37-48 Edward Arnold, London.
52. Hardy P., Abran D., Li D.-Y., Fernandez H., Varma D.R., Chemtob S. Free radicals in retinal and choroidal blood flow autoregulation in the piglet: Interaction with prostaglandins. Inv. Ophthalmol. Vis. Sci. 35:1994;580-591.
53. Haugen G., Hovig T. Studies of autocoid responsiveness and endothelium dependency in human umbilical arteries. Scand. J. Lab. Invest. 52:1992;141-149.
54. Hickam J.B., Frayser R. A photographic method for measuring the mean retinal circulation time using fluorescein. Invest. Ophthalmol. 4:1965;876-884.
55. 2 receptor. Nature. 349:1991;617-620.
56. Hoste A.M. Reduction of IOP with latanoprost (letter). Ophthalmology. 104:1997;895-896.
57. Hoyng P.F.J., Rulo A.H., Greve E.L., Astin M., Gjötterberg M. Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: A review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Surv. Ophthalmol. 41:(Suppl. 2):1997;S83-S88.
58. Jampol L.M. Pharmacologic therapy of aphakic cystoid macular edema. A review. Ophthalmology. 89:1982;891-897.
59. Jampol L.M. Pharmacologic therapy of aphakic and pseudophakic cystoid macular edema. 1985 Update. Ophthalmology. 92:1985;807-810.
60. Jonsson H.T., Middleditch B.S., Desiderio D.M. Prostaglandins in human seminal fluid: Two novel compounds. Science. 187:1975;1093-1094.
61. 2α-induced endothelium-dependent relaxation in isolated monkey cerebral arteries. Am. J. Physiol. 260:1991;H1538-H1543.
62. 1 as a major component of the semen of primates. Nature. 260:1976;544-545.
63. Lippton H.L., McNamara D.B., Armstead W.M., Hyman A.L., Kadowitz P.J. Cardiovascular actions of arachidonic acid metabolites. Curtis-Prior P.B. Prostaglandins. Biology and Chemistry of Prostaglandins and Related Eicosanoids. 1988;217-237 Churchill Livingstone, Edinburgh.
64. Miyake K. Prevention of cystoid macular edema after lens extraction by topical indomethacin. I. A preliminary report. Graefe's Arch. Clin. Exp. Ophthalmol. 203:1977;81-88.
65. Miyake K. Prevention of cystoid macular edema after lens extraction by topical indomethacin. II. A control study in bilateral extractions. Jpn. J. Ophthamol. 22:1978;80-94.
66. Miyake K., Shizuko S., Hana M. Long-term follow-up study on prevention of aphakic cystoid macular edema by topical indomethacin. Br. J. Ophthalmol. 64:1980;324-328.
67. Miyake K., Shirasawa E., Hikita M. Hypotheses on the role of prostaglandins in the pathogenesis of epinephrine maculopathy and aphakic cystoid macular edema. Bito L.Z., Stjernschantz J. The Ocular Effects of Prostaglandins and Other Eicosanoids. 1989;265-276 Alan R. Liss Inc, New York.
68. Miyake K., Ota I., Maekubo K., Ichihasi S., Miyake S. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophobias. Archives of Ophthalmology. 117:(1):1999;34-40.
69. 3 determines G-protein specificity. Nature. 365:1993;166-170.
70. Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors: Structures, properties and functions. Physiol. Rev. 79:1999;1193-1226.
71. Nicolela M.T., Buckley A.R., Walman B.E., Drance S.M. A comparative study on the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels. Am. J. Ophthalmol. 122:1996;784-789.
72. 2α response of isolated calf retinal resistance arteries. Exp. Eye Res. 48:1989;329-335.
73. 2α-1-isopropyl ester in the cynomolgus monkey. Exp. Eye Res. 48:1989;707-716.
74. 2α receptor messenger RNA and protein in the cynomolgus monkey eye. Invest. Ophthalmol. Vis Sci. 37:1996;716-726.
75. Ohkubo B., Chiba S. Vascular reactivities of Simian ophthalmic and ciliary arteries. Curr. Eye Res. 6:1987;1197-1204.
76. Pace-Asciak C.R. Catabolism of the prostanoids and leukotrienes. Curtis-Prior P.B. Prostaglandins. Biology and Chemistry of Prostaglandins and Related Eicosanoids. 1988;46-51 Churchill Livingstone, Edinburgh.
77. Parys-van Ginderdeuren R., Malcolm D., Varma D.R., Aranda J.V., Chemtob S. Dissociation between prostaglandin levels and blood flow to the retina and choroid in the newborn pig after nonsteroidal anti-inflammatory drugs. Invest. Ophthalmol. Vis. Sci. 33:1992;3378-3384.
78. Pennick M., White R.P., Crockarell J.T., Robertson J.T. Role of prostaglandins in genesis of experimental vasospasm. J. Neurol. 37:1972;398-403.
79. Peyman G.A., Bennet T.O., Vichek J. Effects of intravitreal prostaglandins on retinal vasculature. Ann. Ophthalmol. 7:1975;279-288.
80. Pickard J.D., Mackenzie E.T. Inhibition of prostaglandin synthesis and the response of baboon cerebral circulation to carbon dioxide. Nature. 245:1973;187-188.
81. Pierce K.L., Gil D.W., Woodward D.F., Regan J.W. Molecular cloning of human prostanoid receptors. Trends Pharmacol. Sci. 16:1995;253-256.
82. Pierce K.L., Bailey T.J., Hoyer P.B., Gil D.W., Woodward D.F., Regan J.W. Cloning of a carboxyl-terminal isoform of the prostanoid FP receptor. J. Biol. Chem. 272:1997;883-887.
83. Pournaras C., Tsacopoulos M., Chapuis P.H. Studies on the role of prostaglandins in the regulation of retinal blood flow. Exp. Eye Res. 26:1978;687-697.
84. Pournaras C. Autoregulation of ocular blood flow. Kaiser H.J., Hendrickson P. Ocular Blood Flow Glaucoma-Meeting 1995. 1995;40-50 Karger, Basel.
85. Resul B., Stjernschantz J., No K., Liljebris C., Selén G., Astin M., Karlsson M., Bito L.Z. Phenyl-substituted prostaglandins: Potent and selective antiglaucoma agents. J. Med. Chem. 36:1993;243-248.
86. Resul, B. and Stjernschantz, J. (1993) Structure-activity relationships of prostaglandin analogues as ocular hypotensive agents. Curr. Opin. Ther. Patents, 3, 781-795.
87. Rochels R. Tierexperimentelle Untersuchungen zur Rolle von Entzündungsmediatoren bei der Hornhautneovaskularisation. Doc. Ophthalmol. 57:1984;215-262.
88. Rowe J.A., Hattenhauer M.G., Herman D.C. Adverse side effects associated with latanoprost. Am. J. Ophthalmol. 124:1997;683-685.
89. Sakurai M., Araie M., Oshika T., Mori M., Masuda K., Ueno R., Takase M. Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes. Jpn. J. Ophthalmol. 35:1991;156-165.
90. Sakurai M., Araie M., Oshika T., et al. Effects of topical application of UF-021, a novel prostaglandin-related compound, on aqueous humor dynamics in rabbit. Jpn. J. Ophthalmol. 37:1993;252-258.
91. Schuster V.L., Lu R., Coca-Prados M. The prostaglandin transporter is widely expressed in ocular tissues. Surv. Ophthalmol. 41:(Suppl. 2):1997;S41-S45.
92. Seong G.J., Lee H.K., Hong Y.J. Effects of 0.005% latanoprost on optic nerve head and peripapillary retinal blood flow. Ophthalmologica. 213:1999;355-359.
93. Sjöquist B., Basu S., Byding P., Bergh K., Stjernschantz J. The pharmacokinetics of a new antigluacoma drug, latanoprost, in the rabbit. Drug Metabolism and Disposition. 26:1998;745-754.
94. Sjöquist B., Tajallei S., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: Single intravenous oral or topical administration on the eye. Arzneim.-Forsch./Drug Res. 49:1999;240-249.
95. Sjöquist B., Uhlin A., Byding P., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: Repeated topical administration on the eye. Arzneim.-Forsch./Drug Res. 49:1999;234-239.
96. Starr M.S. Further studies on the effect of prostaglandin on intraocular pressure in the rabbit. Exp. Eye Res. 11:1971;170-177.
97. Starr M.S. Effects of prostaglandin on blood flow in the rabbit eye. Exp. Eye Res. 11:1971;161-169.
98. Stjernschantz J. Autacoids and Neuropeptides. Sears M.L. Handbook of Experimental Pharmacology. Vol. 69:1984;311-365 Springer Verlag, Berlin/Heidelberg/New York/Tokyo.
99. 4 in the cat. Prostaglandins. 27:1984;5-16.
100. Stjernschantz J., Nilsson S.F.E., Astin M. Vasodynamic and angiogenic effects of eicosanoids in the eye. Bito L.Z., Stjernschantz J. The Ocular Effects of Prostaglandins and Other Eicosanoids. 1989;155-170 Alan R. Liss Inc, New York.
101. Stjernschantz J., Resul B. Phenyl-substituted prostaglandin analogs for glaucoma treatment. Drugs Future. 17:1992;691-704.
102. 2α analogue. Samuelsson B., et al. Advances in Prostaglandin, Thromboxane and Leukotriene Research. Vol. 23:1995;513-518 Raven Press, New York.
103. Stjernschantz J., Alm A. Latanoprost as a new horizon in the medical management of glaucoma. Curr. Opin. Ophthamol. 7:1996;11-17.
104. Stjernschantz J., Selén G., Ocklind A., Resul B. Effects of latanoprost and related prostaglandin analogues. Alm A., Weinreb R.N. Uveoscleral Outflow. Biology and Clinical Aspects. 1998;57-72 Mosby-Wolfe, London.
105. Stjernschantz J., Selén G., Astin M., Karlsson M., Resul B. Effect of latanoprost on regional blood flow and capillary permeability in the monkey eye. Arch. Ophthalmol. 117:1999;1363-1367.
106. Su E.N., Yu D.-Y., Adler V.A., Cringle S.J. Effects of extracellular pH on agonist-induced vascular tone of the catophthalmociliary artery. Invest. Ophthalmol. Vis. Sci. 35:1994;998-1007.
107. 3 receptor with different carboxyl-terminal domains. J. Biol. Chem. 268:1993;2712-2718.
108. Sugiyama T., Azuma I. Effect of UF-021 on optic nerve hand circulation in rabbits. Jpn J. Ophthalmol. 39:1995;124-129.
109. Taniguchi T., Haque M.S.R., Sugiyama K., et al. Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits. J. Ocul. Pharmacol. 12:1996;489-498.
110. Taylor P.L., Kelly R.W. 19-hydroxylated E prostaglandins of human semen. Nature. 250:1974;665-667.
111. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology. 100:1993;1297-1304.
112. True Gabelt B.A., Kaufman P.L. Prostaglandin F2alpha increases uveoscleral outflow in the cynomolgus monkey. Exp. Eye Res. 49:1989;389-402.
113. Unger W.G. Mediation of the ocular response to injury and irritation: Peptides versus prostaglandins. Bito L.Z., Stjernschantz J. The Ocular Effects of Prostaglandins and Other Eicosanoids. 1989;293-328 Alan R. Liss Inc, New York.
114. 2 receptor from human blood platelets. J. Biol. Chem. 264:1989;16496-16501.
115. 2α-induced contraction. Acta Physiol. Scand. 120:1984;197-205.
116. 2α in the human pial arteries. Acta Physiol. Scand. 121:1984;369-378.
117. Vane J.R., Botting R.M. Overview - mechanisms of action of anti-inflammatory drugs. Vane J., Botting J., Botting R. Improved Non-Steroid Anti-Inflammatory Drugs: COX-2 Enzyme Inhibitors. 1996;1-27 Kluwer Academic Publishers, William Harvey Press, London.
118. 2α-isopropylester eye drops. Effects in normal human eyes. Br. J. Ophthalmol. 73:1989;419-426.
119. Warwar R.E., Bullock J.D., Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use: Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 105:1998;263-268.
120. Watson P., Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 103:1996;126-137.
121. 2 analogue on bovine cerebral arterial tone and calcium fluxes. Stroke. 22:1991;66-72.
122. Whitelock R.A.F., Eakins K.E. Vascular changes in the anterior uvea of the rabbit produced by prostaglandins. Arch. Ophthalmol. 89:1973;495-499.
123. Wistrand P.J., Stjernschantz J., Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv. Ophthalmol. 41:(Suppl. 2):1997;S129-138.
124. Woodward D.F., Ledgard S.E. Comparison of leukotrienes as conjunctival microvascular permeability factors. Ophthalmic Res. 17:1985;318-320.
125. 2 receptor agonist. Prostaglandins. 46:1993;371-383.
126. Woodward D.F., Regan J.W., Lake S., Ocklind A. The molecular biology and ocular distribution of prostanoid receptors. Surv. Ophthalmol. 41:(Suppl. 2):1997;S15-S21.
127. ®; isopropyl unoprostone). Surv. Ophthalmol. 41:(Suppl. 2):1997;S99-S103.
128. Yamamoto T., Kitazawa Y. Iris-color change developed after topical isopropyl unoprostone treatment. J. Glaucoma. 6:1997;430-432.
129. 1 and copper in angiogenesis. J. Nat. Cancer Inst. 69:1982;475-481.
130. 1 and by S 180 cells and on growth of murine transplantable tumours. Int. J. Cancer. 35:1985;549-552.
131. 1 in rabbit cornea. Samuelsson B., et al. Advances in Prostaglandin, Thromboxane and Leukotriene Research. Vol. 23:1995;495-497 Raven Press, New York.